Sionna Therapeutics to Participate in Upcoming March 2026 Investor Conferences

Rhea-AI Summary

Sionna Therapeutics (Nasdaq: SION) announced management will participate in investor fireside chats in March 2026. Events include TD Cowen 46th Annual Health Care Conference on March 2, 2026 at 2:30 p.m. ET and Leerink Partners Global Healthcare Conference on March 10, 2026 at 1:40 p.m. ET.

Live webcasts and replays will be available in the Investors section at https://investors.sionnatx.com/.

News Market Reaction – SION

+1.72%

7 alerts

+1.72% Session close to close

+4.1% Peak in 24 hr 14 min

$1.73B Market Cap

0.2x Rel. Volume

In the Feb 23 session, SION gained 1.72%, reflecting a mild positive market reaction. Argus tracked a peak move of +4.1% during that session. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement adds to Sionna’s steady cadence of investor-relations activity, with March 2026 fi...

Analysis

This announcement adds to Sionna’s steady cadence of investor-relations activity, with March 2026 fireside chats at major healthcare conferences and webcasts via the company’s site. Historically, similar conference notices and the Q3 2025 update have produced varied price reactions, while regulatory filings showed both insider option grants and notable shareholder sales. Investors may watch upcoming clinical readouts and future SEC filings for more decisive fundamental signals.

Key Figures

TD Cowen conference date: March 2, 2026 TD Cowen presentation time: 2:30 p.m. ET Leerink conference date: March 10, 2026 +1 more

4 metrics

TD Cowen conference date March 2, 2026 TD Cowen 46th Annual Health Care Conference presentation date

TD Cowen presentation time 2:30 p.m. ET Scheduled time for Sionna fireside chat

Leerink conference date March 10, 2026 Leerink Partners Global Healthcare Conference presentation date

Leerink presentation time 1:40 p.m. ET Scheduled time for Sionna fireside chat

Historical Context

5 past events · Latest: Feb 04 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Feb 04	Investor conference update	Neutral	-7.1%	Announcement of Guggenheim Emerging Outlook biotech summit presentation and webcast details.
Jan 05	Investor conference update	Neutral	+4.2%	Participation in the 44th Annual J.P. Morgan Healthcare Conference with webcast access.
Nov 24	Investor conferences update	Neutral	+1.6%	Planned fireside chats at two December 2025 healthcare investor conferences.
Nov 05	Earnings and pipeline	Positive	-1.6%	Q3 2025 results plus Phase 2a and Phase 1 trial initiations and strong cash position.
Nov 04	Investor conferences update	Neutral	-1.2%	Scheduled November 2025 fireside chats at Guggenheim and Stifel healthcare conferences.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent history shows SION’s share price often moving meaningfully after neutral or positive events, with all five past announcements showing price reactions that did not neatly match the tone of the news.

Recent Company History

Over the last few months, Sionna has repeatedly highlighted conference participation and one key earnings update. In Nov 2025, it reported Q3 2025 results with cash of $325.0M and progress on Phase 1/2 cystic fibrosis programs, yet the stock moved -1.57% the next day. Several conference announcements in Nov 2025, Jan 2026, and Feb 2026 produced mixed reactions, including a -7.12% move after a February Guggenheim summit notice. Today’s March conference update fits this ongoing investor-relations cadence.

Key Terms

cystic fibrosis, cftr protein, webcasts

3 terms

cystic fibrosis medical

"treatment paradigm for cystic fibrosis (CF) by developing novel medicines"

A genetic disease that causes the body to produce thick, sticky mucus that clogs airways and digestive passages, leading to ongoing lung infections, breathing difficulty, and problems absorbing nutrients. For investors, cystic fibrosis matters because treatments range from symptom management to pricey, targeted drugs that can change patient outcomes; progress in therapies, clinical trial results, regulatory approvals, and reimbursement decisions can significantly affect the commercial value of companies working in this area.

cftr protein medical

"normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein"

A CFTR protein is a protein in the outer membrane of many body cells that acts like a tiny gate controlling the movement of salt and water by letting chloride and bicarbonate ions pass through. Its function matters to investors because defects or malfunctions in this gate cause diseases (most famously cystic fibrosis) and are the direct targets of drugs, diagnostics, and biotech investments—think of it as a valve whose repair or replacement can create major medical and commercial value.

webcasts technical

"Live webcasts of the presentations can be accessed in the ‘Investors’ section"

Webcasts are live or recorded audio and video broadcasts delivered over the internet, often used for earnings calls, investor presentations, and corporate announcements. They let investors see and hear company leaders directly—like watching a live TV show or listening to a podcast—so you can assess tone, get extra detail beyond written reports, and hear answers to questions in real time; that direct access can influence how investors value a company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WALTHAM, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that management will participate in fireside chats at the following upcoming investor events:

• TD Cowen 46^th Annual Health Care Conference on Monday, March 2^nd, 2026, at 2:30 p.m. ET; and
• Leerink Partners Global Healthcare Conference 2026 on Tuesday, March 10^th, 2026, at 1:40 p.m. ET

Live webcasts of the presentations can be accessed in the ‘Investors’ section of Sionna’s website at https://investors.sionnatx.com/. Replays will also be available following the events.

About Sionna Therapeutics 
Sionna Therapeutics is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Sionna’s goal is to deliver differentiated medicines for people living with CF that can restore their CFTR function to as close to normal as possible by directly stabilizing CFTR’s nucleotide binding domain 1 (NBD1), which Sionna believes is central to potentially unlocking dramatic improvements in clinical outcomes and quality of life for people with CF. Leveraging more than a decade of the co-founders’ research on NBD1, Sionna is advancing a pipeline of small molecules engineered to correct the defects caused by the F508del genetic mutation, which occurs in NBD1. Sionna is also developing a portfolio of complementary CFTR modulators that are designed to work synergistically with its NBD1 stabilizers to improve CFTR function. For more information about Sionna, visit www.sionnatx.com.

Sionna intends to use its Investor Relations website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor Sionna’s Investor Relations website, in addition to following Sionna’s press releases, SEC filings, public conference calls, presentations, and webcasts.

Media Contact 
Adam Daley 
CG Life 
212.253.8881 
adaley@cglife.com 

Investor Contact 
Juliet Labadorf 
ir@sionnatx.com 

FAQ

When will Sionna Therapeutics (SION) present at the TD Cowen conference in March 2026?

Sionna will present on March 2, 2026 at 2:30 p.m. ET as a fireside chat. According to the company, the session is part of TD Cowen 46th Annual Health Care Conference and will be available via live webcast in the Investors section.

How can investors watch Sionna Therapeutics (SION) at the Leerink Partners Global Healthcare Conference 2026?

Investors can watch the live webcast on the company's investor site for the March 10, 2026 at 1:40 p.m. ET presentation. According to the company, replays will be posted in the Investors section after the event.

Where is the Sionna Therapeutics (SION) webcast hosted for the March 2026 investor presentations?

The webcast is hosted in the Investors section of Sionna's website at https://investors.sionnatx.com/. According to the company, both live streams and subsequent replays will be accessible there for investor viewing.

What topics will Sionna Therapeutics (SION) management likely cover during the March 2026 fireside chats?

Management will discuss company strategy and clinical-stage programs targeting CFTR function for cystic fibrosis treatment. According to the company, the sessions will focus on recent development priorities and investor updates on clinical programs.

Will replays of Sionna Therapeutics (SION) March 2026 presentations be available after the events?

Yes, replays will be available in the company's investor website following the events. According to the company, recorded versions of both the March 2 and March 10 presentations will be posted in the Investors section for later viewing.